A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in ...

Our most recent episode of The Expert Series podcast explores the newly released SLE treatment guidelines and how they might affect patient care.

The FDA has granted Breakthrough Therapy designation for litifilimab for the treatment of cutaneous lupus erythematosus, a chronic autoimmune skin disease.

AstraZeneca has hit what appears to be a minor speed bump in gaining clearance in the U.S. for its subcutaneous (SC) version of lupus treatment Saphnelo. | AstraZeneca will have to negotiate what ...

Please provide your email address to receive an email when new articles are posted on . Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania Hospital, and chief of ...

There are a few to keep in mind.

Please provide your email address to receive an email when new articles are posted on . Patients with systemic lupus with a history of skin rashes are likely to have high interferon levels. This ...

A regulatory decision is expected by October 2025. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva ®) for the ...

The Lupus Research Alliance applauds the decision by the U.S. Food and Drug Administration (FDA) to grant Breakthrough Therapy designation for litifilimab (BIIB059) in clinical development by Biogen ...

You've changed. And your care plan should too.

Various parts of Medicare offer coverage for lupus treatments. Lupus can also qualify a person for Medicare before they turn 65 years old. Systemic lupus erythematosus (lupus) is a long-term (chronic) ...

Add Yahoo as a preferred source to see more of our stories on Google. For many women living with lupus, the hardest part of the disease isn’t learning the diagnosis, it’s learning how much suffering ...